April 26, 2024

• 

[THE INVESTOR] As of Mar. 22 11:25 A.M., KDPharm declined 1.08%, compared with yesterday, to 18,400 won (US$16.37). It had increased 1.1% through the past month. Standard deviation, which indicates volatility of stock, records 0.9% on the same period over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly earnings rate of KDPharm was the highest, but its volatility within 1 month was the lowest. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was 1.2. Compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, -2.2, and thus the industrial comparison performance was good.

By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.